CTLA4 and neoplasm: Therapeutic strategies utilizing immune checkpoint inhibitors (such as anti-CTLA4 and anti-PD-1 antibodies) have been used to induce anti-tumor immunity in T cells, achieving promising clinical benefits in many types of cancer26.